{"component": "definition", "props": {"groups": [{"snippet": "means, [**].", "size": 8, "snippet_links": [], "samples": [{"hash": "hLWQhrlGWH0", "uri": "/contracts/hLWQhrlGWH0#lead-candidate", "label": "Collaboration and License Agreement (Carisma Therapeutics Inc.)", "score": 36.6577682495, "published": true}, {"hash": "iL6zPI7vxMD", "uri": "/contracts/iL6zPI7vxMD#lead-candidate", "label": "Collaboration and License Agreement (Sesen Bio, Inc.)", "score": 33.8898010254, "published": true}, {"hash": "8KVojHNGz4X", "uri": "/contracts/8KVojHNGz4X#lead-candidate", "label": "Collaboration and License Agreement (Sesen Bio, Inc.)", "score": 33.7830238342, "published": true}], "hash": "c8743fef6d04546273a031f2ce163b8b", "id": 1}, {"snippet": "means, with respect to a given Program, any Collaboration Candidate that Targets the Collaboration Target under such Program that (i) satisfies the Lead Candidate Criteria, or (ii) if no Collaboration Candidate has satisfied the Lead Candidate Criteria at the time when Celgene exercises its IND Option for a given Program, the Collaboration Candidate under such Program that is at the most advanced stage of Development under such Program. It is understood and agreed that a \u201cDevelopment Candidate\u201d shall remain included in the definition of \u201cLead Candidate\u201d.", "size": 7, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "collaboration-candidate", "type": "definition", "offset": [44, 67]}, {"key": "collaboration-target", "type": "definition", "offset": [85, 105]}, {"key": "lead-candidate-criteria", "type": "definition", "offset": [148, 171]}, {"key": "at-the-time", "type": "definition", "offset": [253, 264]}, {"key": "stage-of-development", "type": "clause", "offset": [400, 420]}, {"key": "it-is-understood-and-agreed-that", "type": "definition", "offset": [441, 473]}, {"key": "development-candidate", "type": "definition", "offset": [477, 498]}, {"key": "the-definition-of", "type": "clause", "offset": [525, 542]}], "samples": [{"hash": "1PRlwCf6H1w", "uri": "/contracts/1PRlwCf6H1w#lead-candidate", "label": "Master Collaboration Agreement", "score": 31.3408622742, "published": true}, {"hash": "jyCPZUGoLnP", "uri": "/contracts/jyCPZUGoLnP#lead-candidate", "label": "Master Collaboration Agreement (Prothena Corp PLC)", "score": 29.6242294312, "published": true}, {"hash": "8T8ysQBgaFY", "uri": "/contracts/8T8ysQBgaFY#lead-candidate", "label": "Master Collaboration Agreement (Prothena Corp PLC)", "score": 29.3504447937, "published": true}], "hash": "002da9872c4e80c87b6b4c27fc03a04e", "id": 2}, {"snippet": "means a Regeneron Product or Intellia Liver Product, as applicable, that [***] has been selected by the respective Party for initiation of preclinical studies [***] needed to support an IND and the initiation of GMP manufacturing.", "size": 5, "snippet_links": [{"key": "regeneron-product", "type": "definition", "offset": [8, 25]}, {"key": "intellia-liver-product", "type": "definition", "offset": [29, 51]}, {"key": "preclinical-studies", "type": "clause", "offset": [139, 158]}, {"key": "gmp-manufacturing", "type": "definition", "offset": [212, 229]}], "samples": [{"hash": "78LVdQVCpeu", "uri": "/contracts/78LVdQVCpeu#lead-candidate", "label": "License and Collaboration Agreement (Intellia Therapeutics, Inc.)", "score": 33.3394927979, "published": true}, {"hash": "7jVz9mYByjQ", "uri": "/contracts/7jVz9mYByjQ#lead-candidate", "label": "License and Collaboration Agreement (Intellia Therapeutics, Inc.)", "score": 27.3408622742, "published": true}, {"hash": "1bTMFZYevBf", "uri": "/contracts/1bTMFZYevBf#lead-candidate", "label": "License and Collaboration Agreement (Intellia Therapeutics, Inc.)", "score": 27.3189601898, "published": true}], "hash": "2f1876ac4ef910fd6a4b87fad07fe0ce", "id": 3}, {"snippet": "means up to ten (10) Paratek Compounds that are listed on the Lead Candidate List attached hereto as Schedule 1, as amended from time to time.", "size": 4, "snippet_links": [{"key": "candidate-list", "type": "definition", "offset": [67, 81]}, {"key": "schedule-1", "type": "definition", "offset": [101, 111]}, {"key": "as-amended", "type": "definition", "offset": [113, 123]}, {"key": "from-time-to-time", "type": "clause", "offset": [124, 141]}], "samples": [{"hash": "571CibfsIlI", "uri": "/contracts/571CibfsIlI#lead-candidate", "label": "Collaborative Research and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "fxaDMn4sgun", "uri": "/contracts/fxaDMn4sgun#lead-candidate", "label": "Collaborative Research and License Agreement (Paratek Pharmaceuticals, Inc.)", "score": 26.2484607697, "published": true}, {"hash": "cH3GXdrun5O", "uri": "/contracts/cH3GXdrun5O#lead-candidate", "label": "Collaborative Research and License Agreement (Paratek Pharmaceuticals Inc)", "score": 23.7378501892, "published": true}], "hash": "9c9f7431b2b91133b193b983a1b6c804", "id": 4}, {"snippet": "means a Dynavax ISS or Collaboration ISS that, in accordance with the Joint Research Plan, has been [ * ] at the time of its Lead Candidate Development Decision for further preclinical evaluation.", "size": 4, "snippet_links": [{"key": "in-accordance-with", "type": "definition", "offset": [47, 65]}, {"key": "joint-research-plan", "type": "definition", "offset": [70, 89]}, {"key": "at-the-time", "type": "definition", "offset": [106, 117]}, {"key": "development-decision", "type": "definition", "offset": [140, 160]}], "samples": [{"hash": "i2FbO365PaZ", "uri": "/contracts/i2FbO365PaZ#lead-candidate", "label": "Research Collaboration and License Agreement (Dynavax Technologies Corp)", "score": 22.8288841248, "published": true}, {"hash": "4CLWZHwqUZg", "uri": "/contracts/4CLWZHwqUZg#lead-candidate", "label": "Research Collaboration and License Agreement (Dynavax Technologies Corp)", "score": 20.0, "published": true}, {"hash": "5hPI9n8Ks35", "uri": "https://investors.dynavax.com/static-files/c5e8b7e6-2229-4bc2-b5c7-dfe2eb65318c", "label": "investors.dynavax.com", "score": 9.657084465, "published": false}], "hash": "cbbf2141f80fd68ae0806aaf384a45b1", "id": 5}, {"snippet": "means an Anticalin protein that satisfies all success criteria contained in an initial Collaboration Product Development Plan (which will be prepared by the Parties as set forth in Section 4.3.3.1) and that has been selected for further Research and Development by the JSC.", "size": 4, "snippet_links": [{"key": "anticalin-protein", "type": "definition", "offset": [9, 26]}, {"key": "success-criteria", "type": "definition", "offset": [46, 62]}, {"key": "contained-in", "type": "definition", "offset": [63, 75]}, {"key": "product-development-plan", "type": "definition", "offset": [101, 125]}, {"key": "by-the-parties", "type": "clause", "offset": [150, 164]}, {"key": "research-and-development", "type": "definition", "offset": [237, 261]}], "samples": [{"hash": "kRhsH8TmPUb", "uri": "/contracts/kRhsH8TmPUb#lead-candidate", "label": "License & Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 29.3148536682, "published": true}, {"hash": "evxEGHBtDHG", "uri": "/contracts/evxEGHBtDHG#lead-candidate", "label": "License & Collaboration Agreement (Pieris Pharmaceuticals, Inc.)", "score": 28.6084880829, "published": true}, {"hash": "hSKa1F23GyT", "uri": "https://ir.palvellatx.com/static-files/56d2d0f8-efe4-49a2-a2f4-2e7ad8b70264", "label": "Amendment", "score": 18.8748378754, "published": false}], "hash": "b7a8b17d04c926918b9ffbdd3f01a039", "id": 6}, {"snippet": "means, with respect to a particular Available Target, a Compound Directed to such Available Target that is selected by the JRC pursuant to Section 2.2.4 as meeting the applicable Lead Candidate Criteria, or is otherwise designated a Lead Candidate pursuant to Section 2.2.4.", "size": 4, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "available-target", "type": "definition", "offset": [36, 52]}, {"key": "directed-to", "type": "definition", "offset": [65, 76]}, {"key": "the-jrc", "type": "clause", "offset": [119, 126]}, {"key": "pursuant-to-section", "type": "definition", "offset": [127, 146]}, {"key": "the-applicable", "type": "clause", "offset": [164, 178]}, {"key": "lead-candidate-criteria", "type": "definition", "offset": [179, 202]}], "samples": [{"hash": "55MbZxtoZIy", "uri": "/contracts/55MbZxtoZIy#lead-candidate", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 24.3620815277, "published": true}, {"hash": "jP7QA96PSW7", "uri": "/contracts/jP7QA96PSW7#lead-candidate", "label": "Collaboration and License Agreement (Epizyme, Inc.)", "score": 24.2197132111, "published": true}], "hash": "bcdf9453768dfe9a21286c9019f51f19", "id": 7}, {"snippet": "means, on Candidate Research Program-by-Candidate Research Program basis, the ADC candidate selected by the JRDC at the [***] to [***].", "size": 3, "snippet_links": [{"key": "research-program", "type": "definition", "offset": [20, 36]}], "samples": [{"hash": "zoftSHBapV", "uri": "/contracts/zoftSHBapV#lead-candidate", "label": "Collaboration and Option Agreement (Immunogen Inc)", "score": 28.8548946381, "published": true}, {"hash": "gY7FylzczcR", "uri": "https://immunogen.gcs-web.com/static-files/ed8e84bf-aa08-4690-a318-e2dd11db3430", "label": "immunogen.gcs-web.com", "score": 14.8220300674, "published": false}, {"hash": "j7WHyaVMCKF", "uri": "https://investor.immunogen.com/static-files/ed8e84bf-aa08-4690-a318-e2dd11db3430", "label": "investor.immunogen.com", "score": 9.1752223969, "published": false}], "hash": "f60e98d07922c27a06ee06e834a45de5", "id": 8}, {"snippet": "means, with respect to a Program, a Program Compound that meets the criteria set forth in the R&D Plan for such Program and that the SOC determines warrants further advancement with a goal of qualification as a Development Candidate.", "size": 3, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "program-compound", "type": "definition", "offset": [36, 52]}, {"key": "the-criteria", "type": "clause", "offset": [64, 76]}, {"key": "rd-plan", "type": "definition", "offset": [94, 102]}, {"key": "development-candidate", "type": "definition", "offset": [211, 232]}], "samples": [{"hash": "k6ioPFDpuhr", "uri": "/contracts/k6ioPFDpuhr#lead-candidate", "label": "Collaboration, License and Option Agreement (Curis Inc)", "score": 32.2032852173, "published": true}, {"hash": "a2jP81icHKG", "uri": "/contracts/a2jP81icHKG#lead-candidate", "label": "Collaboration, License and Option Agreement", "score": 31.3408622742, "published": true}, {"hash": "dO0MNV8xez7", "uri": "/contracts/dO0MNV8xez7#lead-candidate", "label": "Collaboration, License and Option Agreement (Curis Inc)", "score": 26.1471595764, "published": true}], "hash": "c891a562d0459c0442fb450e96c5ca2a", "id": 9}, {"snippet": "means any ***** TandAb (a) which is identified by Affimed or any of its Affiliates, or any Third Party acting on Affimed\u2019s or its Affiliates behalf, in the performance of its ***** activities hereunder and (b) which meets the specifications set forth in the Development Plan.", "size": 3, "snippet_links": [{"key": "third-party", "type": "clause", "offset": [91, 102]}, {"key": "in-the-performance", "type": "clause", "offset": [149, 167]}, {"key": "the-specifications", "type": "definition", "offset": [222, 240]}, {"key": "the-development-plan", "type": "clause", "offset": [254, 274]}], "samples": [{"hash": "gbNwe9mC1D8", "uri": "/contracts/gbNwe9mC1D8#lead-candidate", "label": "License and Development Agreement", "score": 31.3408622742, "published": true}, {"hash": "kJmvm5PQx5O", "uri": "/contracts/kJmvm5PQx5O#lead-candidate", "label": "License and Development Agreement (Affimed N.V.)", "score": 26.226556778, "published": true}, {"hash": "3PyalUQi8n9", "uri": "/contracts/3PyalUQi8n9#lead-candidate", "label": "License and Development Agreement (Affimed Therapeutics B.V.)", "score": 25.4846000671, "published": true}], "hash": "61631a436a80e8092dea883743814976", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXbGVhZC1jYW5kaWRhdGUjMDAwMDAwMGEMogECZW4YACAA", "definition": {"snippet": "means, [**].", "title": "Lead Candidate", "size": 117, "id": "lead-candidate", "examples": ["If the JSC determines that any back up Oncology Compound to the proposed Oncology <strong>Lead Candidate</strong> should be considered alongside the proposed Oncology <strong>Lead Candidate</strong>, then the JSC may unanimously agree to extend the Oncology Development Candidate Decision Deadline if the JSC determines AstraZeneca should have additional time to consider both candidates before making a decision as to which may be selected as the Oncology Development Candidate.", "After the activities set forth in the applicable Drug Discovery Plan are completed for a particular Collaboration Program, Isis will deliver to the JSC the applicable <strong>Lead Candidate</strong> Data Package for review by the JSC as soon as reasonably practicable for the JSC to determine whether or not the <strong>Lead Candidate</strong> has met the applicable Development Candidate Success Criteria and whether the JSC (or AstraZeneca) wishes to designate a Development Candidate.", "As promptly as possible (but no later than [***] days after AstraZeneca receives such <strong>Lead Candidate</strong> Data Package) (each such [***]-day deadline, which AstraZeneca has determined is sufficient for AstraZeneca to complete its candidate selection identification criteria analysis, an \u201cOncology Development Candidate Decision Deadline\u201d), AstraZeneca will determine whether to select the Oncology <strong>Lead Candidate</strong> (or another Oncology Compound) as an Oncology Development Candidate.", "For clarity, in connection with the Oncology Collaboration, such disclosure would not involve disclosing a Reserved Target or an Oncology <strong>Lead Candidate</strong> until such target had become a Development Candidate unless agreed otherwise by the Parties.", "At such meeting (if possible), or within [***] after such meeting, the JSC (or, if the JSC cannot agree, AstraZeneca) will determine and record in the JSC minutes the determination whether such <strong>Lead Candidate</strong> has met the applicable Development Candidate Success Criteria.", "If AstraZeneca selects the Oncology <strong>Lead Candidate</strong> or any other Oncology Compound as an Oncology Development Candidate, then AstraZeneca will notify Ionis of such selection by the Oncology Development Candidate Decision Deadline and will pay Ionis the Designation of Oncology Development Candidate milestone payment under Section 8.6 within 30 days after AstraZeneca\u2019s receipt of an invoice from Ionis.", "The intent of the Oncology Collaboration is (i) for \u2587\u2587\u2587\u2587 to generate an Oncology <strong>Lead Candidate</strong> for each of the Oncology Collaboration Programs, (ii) with respect to each such Oncology <strong>Lead Candidate</strong>, for AstraZeneca to perform certain in vitro and in vivo (animal) experiments to support their designation, and (iii) for AstraZeneca to conduct IND-Enabling Toxicology Studies with the Oncology Development Candidate.", "If \u2587\u2587\u2587\u2587 believes that a [***] Compound identified in the <strong>Lead Candidate</strong> Data Package satisfies the [***] Success Criteria, but the JSC fails to designate such [***] Compound a Development Candidate, the matter shall be resolved in accordance with Section 12.1.1 and if applicable Section 12.1.3.", "Each time Isis delivers to the JSC a <strong>Lead Candidate</strong> Data Package for a Collaboration Program under this Section 1.14 the Parties will schedule a meeting of the JSC to occur within [***] following delivery of such <strong>Lead Candidate</strong> Data Package.", "For clarity, the expiration of the Disease Research Term will not affect AstraZeneca\u2019s rights or Isis\u2019 obligations with respect to Collaboration Programs under this Agreement, including, in the case of Collaboration Programs, Isis\u2019 obligation under Section 1.13.1 to use Commercially Reasonable Efforts to identify a <strong>Lead Candidate</strong> for each applicable Collaboration Program that satisfies the Development Candidate Success Criteria."], "related": [["development-candidate", "Development Candidate", "Development Candidate"], ["product-candidate", "Product Candidate", "Product Candidate"], ["lead-compound", "Lead Compound", "Lead Compound"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["collaboration-target", "Collaboration Target", "Collaboration Target"]], "related_snippets": [], "updated": "2026-02-07T04:24:37+00:00"}, "json": true, "cursor": ""}}